SENXUAN(BJ:830946)2024-02-26 16:00Financial Performance - The company's operating revenue for 2023 is expected to be ¥589,560,024.01, a decrease of 5.46% compared to the previous year[3] - The net profit attributable to shareholders is projected to be ¥134,483,784.51, down 16.23% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses is estimated at ¥127,020,056.58, a decline of 15.29%[5] - The basic earnings per share is expected to be ¥0.3150, reflecting a decrease of 16.25% compared to the previous year[5] Assets and Equity - Total assets at the end of the reporting period are projected to be ¥1,330,477,152.13, an increase of 2.89% year-on-year[5] - Shareholders' equity attributable to the company is expected to reach ¥1,135,879,586.43, up 4.53% from the beginning of the period[5] - The increase in total assets and shareholders' equity is mainly due to the realization of net profit for the year[6] Market Factors - The decline in revenue is primarily due to decreased demand for antiviral drug solvents and intensified competition, particularly in the Indian market[6] - The overall decrease in net profit is attributed to falling product prices and reduced operating revenue, impacting gross margins[6] Financial Reporting - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the annual report[8]